胶质母细胞瘤在0.35T磁共振成像-直线加速器放化疗期间的每日演化动态
研究对胶质母细胞瘤患者在放化疗期间使用0.35T磁共振成像-直线加速器每日成像,并与独立高场磁共振对比。结果显示64%患者病灶增长、46%患者手术腔缩小,病灶平均迁移距离1.3厘米。作者认为手术腔缩小可缩小 margins,未切除或增长病灶可能需扩大 margins,有限体积推量试验可考虑触发钆对比剂给药。
要点
- 放化疗期间每日MRI-linac成像可见胶质母细胞瘤解剖变化。
- 64%患者病灶增长,46%患者手术腔缩小。
- 病灶平均迁移距离1.3厘米,手术腔0.6厘米。
核心结论
- 放化疗期间每日MRI-linac成像可见胶质母细胞瘤患者解剖变化,手术腔缩小可缩小 margins,未切除或增长病灶可能需扩大 margins 以覆盖变化。
- 作者认为有限体积胶质母细胞瘤推量试验可考虑在非对比MRI-linac发现病灶增长时触发钆对比剂给药以评估自适应放疗。
研究设计与样本
- 前瞻性研究,36例胶质母细胞瘤患者在放化疗期间每日于0.35T MRI-linac成像,并在独立高场MRI三个时间点行对比与非对比成像。
- 分析肿瘤或水肿(病灶)及手术腔在整个治疗中的动态,并与独立T1增强(T1+C)和T2体积比较。
主要发现
- 36例中8例仅手术腔、12例仅病灶、16例两者均有;MRI-linac扫描显示64%患者病灶增长、46%患者手术腔缩小。
- 病灶平均MRI-linac迁移距离1.3厘米(范围0-4.1厘米),手术腔0.6厘米(范围0.1-2.1厘米)。
- 独立MRI与MRI-linac体积强相关:R2=0.991(T2 vs MRI-linac手术腔)、0.972(T1+C vs MRI-linac手术腔)、0.973(T2 vs MRI-linac病灶);T1+C与MRI-linac病灶中度相关(R2=0.609)。
- 有全部扫描的35例患者中,治疗前至治疗后T1+C与MRI-linac病灶同向变化(缩小6例、增长12例、不变8例)共26例(74%);另9例(26%)MRI-linac病灶增长而T1+C成分缩小;无患者T1+C病灶增长而MRI-linac病灶缩小。
临床怎么用
- 作者认为手术腔缩小可缩小 margins 以保留正常脑组织。
- 作者认为未切除或增长病灶可能需扩大 margins 以覆盖变化。
- 作者认为有限体积胶质母细胞瘤推量试验可考虑在非对比MRI-linac发现病灶增长时触发钆对比剂给药以评估自适应放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma changes during chemoradiation therapy are inferred from magnetic resonance imaging (MRI) before and after treatment but are rarely investigated due to logistics of frequent MRI. Using a combination MRI-linear accelerator (MRI-linac), we evaluated changes during daily chemoradiation therapy. METHODS AND MATERIALS: Patients with glioblastoma were prospectively imaged daily during chemoradiation therapy on 0.35T MRI-linac and at 3 timepoints with and without contrast on standalone high-field MRI. Tumor or edema (lesion) and resection cavity dynamics throughout treatment were analyzed and compared with standalone T1 postcontrast (T1+C) and T2 volumes. RESULTS: Of 36 patients included in this analysis, 8 had cavity only, 12 had lesion only, and 16 had both cavity and lesion. Of these, 64% had lesion growth and 46% had cavity shrinkage during treatment on MRI-linac scans. The average MRI-linac migration distance was 1.3 cm (range, 0-4.1 cm) for lesion and 0.6 cm (range, 0.1-2.1 cm) for cavity. Standalone versus MRI-linac volumes correlated strongly with R2 values: 0.991 (T2 vs MRI-linac cavity), 0.972 (T1+C vs MRI-linac cavity), and 0.973 (T2 vs MRI-linac lesion). There was a moderate correlation between T1+C and MRI-linac lesion (R2 = 0.609), despite noncontrast MRI-linac inability to separate contrast enhancement from surrounding nonenhancing tumor and edema. From pretreatment to posttreatment in patients with all available scans (n = 35), T1+C and MRI-linac lesions changed together-shrank (n = 6), grew (n = 12), or unchanged (n = 8)-in 26 (74%) patients. Another 9 patients (26%) had growth on MRI-linac, although the T1+C component shrank. In no patient did T1+C lesion grow while MRI-linac lesion shrank. CONCLUSIONS: Anatomic changes are seen in patients with glioblastoma imaged daily on MRI-linac throughout the chemoradiation therapy course. As surgical resection cavities shrink, margins may be reduced to save normal brain. Patients with unresected or growing lesions may require margin expansions to cover changes. Limited volume glioblastoma boost trials could consider triggered gadolinium contrast administration for evaluation of adaptive radiation therapy when lesion growth is seen on noncontrast MRI-linac.
引用
- Cullison K, Samimi K, Bell JB, et al. Dynamics of Daily Glioblastoma Evolution During Chemoradiation Therapy on the 0.35T Magnetic Resonance Imaging-Linear Accelerator. Int J Radiat Oncol Biol Phys. 2024. PMID: 39357789. doi:10.1016/j.ijrobp.2024.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。